Ifetroban

DRUG3 trials

Sponsors

Cumberland Pharmaceuticals, Brigham and Women's Hospital

Conditions

Aspirin-Sensitive Asthma With Nasal PolypsAspirin-exacerbated Respiratory DiseaseAsthma, Aspirin-InducedCardiomyopathy, DilatedDuchenne Muscular Dystrophy CardiomyopathyLiver CirrhosisNasal PolypsPortal Hypertension

Phase 2

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

CompletedNCT02802228

Cumberland PharmaceuticalsLiver Cirrhosis, Portal Hypertension

Start: 2017-03-06End: 2018-07-17Updated: 2022-01-19

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

CompletedNCT03326063

Brigham and Women's HospitalAspirin-exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps, Asthma, Aspirin-Induced +1

Start: 2018-04-26End: 2023-04-15Updated: 2023-07-14

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

CompletedNCT03340675

Cumberland PharmaceuticalsCardiomyopathy, Dilated, Duchenne Muscular Dystrophy Cardiomyopathy

Start: 2020-10-19End: 2026-01-23Updated: 2026-03-17

Related Papers

Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy.

2021-05-284 citations